Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Launched by BAYER · May 4, 2019

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A diagnosis of wAMD.
• • Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice.
• • Treatment-naïve in the study eye (no prior therapy for wAMD).
• • Patient age ≥50 years of age.
• • Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).
• Exclusion Criteria:
• • Participation in an investigational program with interventions outside of routine clinical practice.
• • Patients with contraindications to IVT aflibercept listed in the local marketing authorization.
• • Planned treatment regimen outside of the local marketing authorization.
• • Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.
• • Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye.
• • Any other retinal disease which may interfere with the treatment of wAMD.